Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover it can improve long-term survival in patients with primary biliary cirrhosis.
Significant improvement in liver health can be achieved during UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases.
The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is expected to witness a CAGR of 7.0% over the forecast period (2018 – 2026).
Increasing prevalence of gall stones and cystic fibrosis is expected to drive growth of the ursodeoxycholic acid market
Ursodeoxycholic acid is increasingly being used for the treatment of chronic cholestatic liver diseases. Increasing prevalence of cystic fibrosis and gall stones is a major factor driving growth of the global ursodeoxycholic acid market during the forecast period. According to the Cystic Fibrosis Foundation 2015 data, around 30,000 people suffered from cystic fibrosis in the U.S. Moreover, around 1,000 new cases of cystic fibrosis are diagnosed in the country, annually. According to the American Gastroenterological Association 2017 report, gallstones is affecting 10-15% of the U.S. population annually, which accounts for around 25 million people.
Women are more likely to develop gallstones in comparison to men. High estrogen levels during pregnancy, birth control pills or hormone replacement therapy are the major factors that produce gallstones in women. Moreover, occurrence of gallstones is also high in older adults and individuals with a family history of gallstones. Surgery is the usual treatment for symptomatic gallstones, however treatment with ursodeoxycholic acid can dissolve smaller stones, which are made mainly of cholesterol.
• Global Ursodeoxycholic Acid Market, By Dosage Form:
• Global Ursodeoxycholic Acid Market, By Mode of Extraction:
• Global Ursodeoxycholic Acid Market, By Application:
◦ Cystic Fibrosis
◦ Liver Cirrhosis
• Global Ursodeoxycholic Acid Market, By Region:
◦ North America
▪ Asia Pacific
▪ Latin America
▪ Middle East
Ursodeoxycholic Acid Market - Competitive Landscape
Key players operating in the global ursodeoxycholic acid market include, Abil Chempharma, Arcelor Chemicals, Biotavia Labs, Daewoong Chemical, Dipharma Francis, Erregierre, Grindeks, ICE, Mitsubishi Tanabe, Pharma Zell, Suzhou Tianlu, and Zhangshanbelling.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2199
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Email: [email protected]